Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.38 per share a year ago. These figures are

Cheap Valuation & Tariff Immunity: Is it Time to Bet on EPD Stock?
Cheap Valuation & Tariff Immunity: Is it Time to Bet on EPD Stock?

Enterprise Products Partners LP EPD appears undervalued, currently trading at a trailing 12-month enterprise value to EBITDA (EV/EBITDA) of 10.28x. This represents a discount compared with the

Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment?
Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment?

It’s been a mostly bullish earnings season for casino stocks with names like MGM Resorts International (NYSE: MGM) and Las Vegas Sands Corp. (NYSE: LVS) having posted solid earnings. But the third

Walmart (WMT) Surpasses Q1 Earnings and Revenue Estimates
Walmart (WMT) Surpasses Q1 Earnings and Revenue Estimates

Walmart (WMT) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.60 per share a year ago. These figures are

Gambling.com Group Limited (GAMB) Q1 Earnings and Revenues Surpass Estimates
Gambling.com Group Limited (GAMB) Q1 Earnings and Revenues Surpass Estimates

Gambling.com Group Limited (GAMB) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.20 per share a year

TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates

TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.54 per share a year ago

Best Value Stocks to Buy for May 15th
Best Value Stocks to Buy for May 15th

Here are three stocks with buy rank and strong value characteristics for investors to consider today, May 15th:  

Intercorp Financial Services IFS: This company which provides financial products and

5 Stocks That Recently Hiked Their Dividend to Reward Investors
5 Stocks That Recently Hiked Their Dividend to Reward Investors

Major U.S. indexes, such as the Nasdaq Composite, the S&P 500, and the Dow Jones Industrial Average, have lost their ground by 13.5%, 8.6%, and 6.9%, respectively, year to date, due to President

5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil

The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative artificial intelligence (genAI) and digital therapeutics, which market

3 Must-Buy U.S. Corporate Behemoths Despite Recent Volatility
3 Must-Buy U.S. Corporate Behemoths Despite Recent Volatility

Wall Street has suffered severe volatility in the past two months. Sticky inflation, a series of weak economic data and the Trump administration’s imposition of reciprocal tariffs raised concerns

SLB Launches Electris Tech to Boost Well Production and Recovery
SLB Launches Electris Tech to Boost Well Production and Recovery

SLB SLB, an American oilfield services company, has launched Electris, a new portfolio of digitally enabled electric well completion technologies designed to enhance hydrocarbon recovery and lower

Are these 3 Top-Ranked Mutual Funds In Your Retirement Portfolio?
Are these 3 Top-Ranked Mutual Funds In Your Retirement Portfolio?

Investing in mutual funds for retirement is never too late. And the Zacks Mutual Fund Rank can be an excellent tool for investors looking to invest in the best funds.

How can you tell a good mutual

Should You Add These 3 Top-Performing Mutual Funds to Your Portfolio?
Should You Add These 3 Top-Performing Mutual Funds to Your Portfolio?

There is never a wrong time to invest in mutual funds for retirement. So, if you're still looking for the best mutual funds, the Zacks Mutual Fund Rank can be a great guide.

The easiest, most

Make the Most of Your Retirement with These Top-Ranked Mutual Funds
Make the Most of Your Retirement with These Top-Ranked Mutual Funds

It is never too late to invest in mutual funds for retirement. As such, if you plan to invest in some of the best funds, the Zacks Mutual Fund Rank can provide you with valuable guidance.

The

Dillard's (DDS) Q1 Earnings Top Estimates
Dillard's (DDS) Q1 Earnings Top Estimates

Dillard's (DDS) came out with quarterly earnings of $10.39 per share, beating the Zacks Consensus Estimate of $9.10 per share. This compares to earnings of $11.09 per share a year ago. These figures

NIKE Vs adidas: Who's Winning the Race in the Athletic Footwear Arena?
NIKE Vs adidas: Who's Winning the Race in the Athletic Footwear Arena?

In the high-stakes world of athletic apparel and footwear, a few rivalries are as iconic or as competitive as that between NIKE Inc. NKE and adidas AG ADDYY. Operating in the expansive and

Steepening Yield Curve? These 3 Bank Stocks Are Poised to Profit
Steepening Yield Curve? These 3 Bank Stocks Are Poised to Profit

The financial markets are full of clues and queues for investors to consider when they are looking for the next path forward in their portfolios. Though some of these factors aren’t as clear-cut

Equinor Warns Europe of LNG Supply Strain Amid Asia Competition
Equinor Warns Europe of LNG Supply Strain Amid Asia Competition

Equinor ASA EQNR, the Norwegian energy major, has warned that Europe will need to offer competitive prices to attract sufficient liquefied natural gas (LNG) supplies to refill its depleted storage

Home Depot's Setup Looks Strong: Invest Before Earnings or Hold Back?
Home Depot's Setup Looks Strong: Invest Before Earnings or Hold Back?

The Home Depot, Inc. HD is set to report first-quarter fiscal 2025 results on May 20, before market open. The company’s top line is expected to have increased year over year in the to-be-reported

CoreWeave Q1 Revenues Beat Estimates, Earnings Down Y/Y, Stock Tanks
CoreWeave Q1 Revenues Beat Estimates, Earnings Down Y/Y, Stock Tanks

CoreWeave, Inc. CRWV reported first-quarter 2025 loss per share of $1.49, which was much wider than a loss of 62 cents in the year-ago quarter. Loss per share includes $177 million of stock-based

Best Income Stocks to Buy for May 15th
Best Income Stocks to Buy for May 15th

Here are three stocks with buy rank and strong income characteristics for investors to consider today, May 15th:

Usinas Siderurgicas de Minas Gerais USNZY: This company which is Latin America's

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.

Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025

As of mid-May 2025, the S&P 500 has turned positive year-to-date (YTD) for the first time in many weeks. Stocks across multiple sectors have broadly recovered from the jolt of tariff news and

Blade Mobility Stock Soars—Is This SPAC Finally Taking Off?
Blade Mobility Stock Soars—Is This SPAC Finally Taking Off?

Shares of Blade Mobility Inc. (NASDAQ: BLDE) are up more than 18% the day after the company delivered its first quarter earnings.

[content-module:CompanyOverview|NASDAQ:BLDE]

Blade Mobility

Is It Time to Buy the Dip in Novo Nordisk Stock?
Is It Time to Buy the Dip in Novo Nordisk Stock?
[content-module:CompanyOverview|NYSE:NVO]

Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is still down nearly 50% in 2025. However, the stock is now